Xcout Intel
Dendreon
Dendreon was a biotechnology company that developed and commercialized Provenge (sipuleucel-T), an autologous cellular immunotherapy for metastatic castration-resistant prostate cancer. It served patients with advanced prostate cancer and the physicians and healthcare providers treating them; the company filed for bankruptcy in 2014 and its assets were subsequently acquired.
Subscribe to see Dendreon’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Dendreon at a glance
Dendreon is a biotech company headquartered in United States, founded in 1992. Xcout recorded 9 job postings from Dendreon in the last 90 days.
Hiring at Dendreon
Xcout recorded 9 job postings from Dendreon in the last 90 days, from a hiring record Xcout has kept since September 2026.
The weekly hiring trend, the roles and locations behind it — see Dendreon's hiring signals →
Get Dendreon's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Dendreon in Xcout Intel
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access